Biolinerx Ltd (NASDAQ:BLRX) has grabbed attention from the analysts, when it saw a value decrease of -0.05% or 0 points in the last trading session to close at $0.41. A total of 1.62 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 976.32 Million shares, while its relative volume stands at 1.68. Biolinerx Ltd (NASDAQ:BLRX) has a market cap of $44.28 Million and the number of outstanding shares have been calculated 108.08 Million.
Shares of Biolinerx Ltd (NASDAQ:BLRX) currently have an Average Brokerage Recommendation of 1, number of Recs in ABR is 3 while industry rank of the company by ABR is out of 255. Out of the analyst recommendations 1 rate Biolinerx Ltd (NASDAQ:BLRX) stock a Buy, 3 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Taking a glance at where the stock might be directed in the future, on a consensus basis, the sell-side has a 52 week price target of $3 on the stock, this valuation is based on 4 number of opinions. The most optimistic analyst sees the stock reaching $4 while the most conventional has $2 target price.
Biolinerx Ltd (NASDAQ:BLRX) as of recent trade, has shown weekly downbeat performance of -6.63% which was maintained at -31.71% in 1-month period. During the past three months the stock slid -42.48%, bringing six months performance to -53.43%. Yearly performance of the stock shows a bearish trend of -57.76% while year-to-date (YTD) performance reflected -6.31% negative outlook.
While taking a glance at financials, we can look at a number of key indicators. Biolinerx Ltd (NASDAQ:BLRX) has trailing twelve month Return on Assets of 0%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of 0% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Biolinerx Ltd (NASDAQ:BLRX) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Biolinerx Ltd (NASDAQ:BLRX)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 0.
The company’s quick ratio for most recent quarter is 0 along with current ratio for most recent quarter of 0. Total debt to equity ratio of the company for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.